Opus Genetics (IRD) Gains from Investment Securities (2018 - 2020)
Opus Genetics (IRD) posted quarterly Gains from Investment Securities of -$100637.0 for Q3 2020, up 58.56% year-over-year from -$63468.7 in Q4 2019, and down 159.65% quarter-over-quarter from $168702.0 in Q2 2020.
Opus Genetics (IRD) Gains from Investment Securities (2018 - 2020) Analysis & Trends
Opus Genetics (IRD) has reported Gains from Investment Securities for 3 consecutive years, with -$100637.0 the latest figure, recorded in Q3 2020.
- In Q3 2020, Gains from Investment Securities rose 58.56% year-over-year to -$100637.0; the TTM figure through Sep 2020 stood at $44302.0 (up 101.11% YoY), while the FY2019 annual figure was -$2.3 million, up 59.14% from the prior year.
- Gains from Investment Securities eased to -$100637.0 in Q3 2020 per IRD's latest filing, from $168702.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $710065.0 in Q3 2018 and bottomed at -$3.4 million in Q1 2018.
- Historically, Gains from Investment Securities has averaged -$698678.3 across 3 years, with a median of -$242860.0 in 2019.
- Annual changes were most pronounced in 2019 — Gains from Investment Securities tumbled 134.2% — and 2020, when it soared 139.46%.
- Opus Genetics' Gains from Investment Securities stood at -$1.8 million in 2018, then jumped by 95.42% to -$82155.0 in 2019, then declined by 22.5% to -$100637.0 in 2020.
- Business Quant data shows IRD's Gains from Investment Securities at -$100637.0 in Q3 2020, $168702.0 in Q2 2020, and $58392.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Opus Genetics | 298.36 Mn | 209.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -100,637.00 |
| Sep 30, 2020 | -100,637.00 |
| Jun 30, 2020 | 168,702.00 |
| Jun 30, 2020 | 168,702.00 |
| Mar 31, 2020 | 58,392.00 |
| Mar 31, 2020 | 58,392.00 |
| Dec 31, 2019 | -82,155.00 |
| Dec 31, 2019 | -82,155.00 |
| Sep 30, 2019 | -242,860.00 |
| Sep 30, 2019 | -242,860.00 |
| Jun 30, 2019 | -427,483.00 |
| Jun 30, 2019 | -427,483.00 |
| Mar 31, 2019 | -1.51 Mn |
| Mar 31, 2019 | -1.51 Mn |
| Dec 31, 2018 | -1.79 Mn |
| Dec 31, 2018 | -1.79 Mn |
| Sep 30, 2018 | 710,065.00 |
| Sep 30, 2018 | 710,065.00 |
| Jun 30, 2018 | -1.10 Mn |
| Jun 30, 2018 | -1.10 Mn |